Scholarlink

Purpose <p>Atrial fibrillation (AF) drives cardioembolic stroke, yet paroxysmal AF (PAF) often escapes detection in embolic stroke of undetermined source (ESUS). We evaluated whether atrial natriuretic peptide (ANP) can identify latent PAF in ESUS, compared with brain natriuretic peptide (BNP).</p> Methods <p>Prospective single-center cohort of ESUS patients admitted within 24&#xa0;h without admission AF. Admission ANP/BNP were assayed; PAF was screened by 14-day continuous ECG. Patients were grouped as PAF-detected or ESUS. Logistic regression (LAD, ANP, BNP) and ROC assessed diagnostic performance.</p> Results <p>Of 567 patients with cerebral infarction, 111 met the criteria for ESUS, and 64 were included after exclusions. PAF was detected in 30 patients, and 34 remained classified as ESUS. Baseline comparisons showed significant differences in age, ANP, BNP, and LAD. In multivariable logistic regression analysis, ANP was independently associated with PAF detection (<i>p</i> = 0.015), whereas BNP and LAD were not. ROC analysis showed an AUC of 0.901 (95% CI, 0.818–0.984) for ANP and 0.892 (95% CI, 0.811–0.973) for BNP, with no significant difference between them (<i>p</i> = 0.821). ANP demonstrated clinically useful performance with a cutoff value of 63.9 pg/mL (sensitivity 94.1%, specificity 83.3%).</p> Conclusions <p>ANP was identified as an independent predictor of PAF detection in patients with ESUS, with strong ROC performance. Given its atrial origin and very short half-life, ANP may serve as an atrium-specific biomarker reflecting acute atrial load, potentially enabling earlier identification of latent PAF in the acute phase.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Atrial natriuretic peptide can be biomarker for predicting atrial fibrillation in embolic stroke of undetermined source

  • 期刊论文

  • 发表日期：

    2026年6月17日

查看全文
  • Yuya Kobayashi,
  • Chinami Yuzawa,
  • Minori Kurashina,
  • Kazuki Kasuga,
  • Yoshiki Hanaoka,
  • Yusaku Shimizu,
  • Atsushi Sato,
  • Kazuhiro Hongo,
  • Yuji Ueno,
  • Yoshiki Sekijima

摘要

Purpose

Atrial fibrillation (AF) drives cardioembolic stroke, yet paroxysmal AF (PAF) often escapes detection in embolic stroke of undetermined source (ESUS). We evaluated whether atrial natriuretic peptide (ANP) can identify latent PAF in ESUS, compared with brain natriuretic peptide (BNP).

Methods

Prospective single-center cohort of ESUS patients admitted within 24 h without admission AF. Admission ANP/BNP were assayed; PAF was screened by 14-day continuous ECG. Patients were grouped as PAF-detected or ESUS. Logistic regression (LAD, ANP, BNP) and ROC assessed diagnostic performance.

Results

Of 567 patients with cerebral infarction, 111 met the criteria for ESUS, and 64 were included after exclusions. PAF was detected in 30 patients, and 34 remained classified as ESUS. Baseline comparisons showed significant differences in age, ANP, BNP, and LAD. In multivariable logistic regression analysis, ANP was independently associated with PAF detection (p = 0.015), whereas BNP and LAD were not. ROC analysis showed an AUC of 0.901 (95% CI, 0.818–0.984) for ANP and 0.892 (95% CI, 0.811–0.973) for BNP, with no significant difference between them (p = 0.821). ANP demonstrated clinically useful performance with a cutoff value of 63.9 pg/mL (sensitivity 94.1%, specificity 83.3%).

Conclusions

ANP was identified as an independent predictor of PAF detection in patients with ESUS, with strong ROC performance. Given its atrial origin and very short half-life, ANP may serve as an atrium-specific biomarker reflecting acute atrial load, potentially enabling earlier identification of latent PAF in the acute phase.